On this page
Rybrevant
amivantamab-vmjw
351(a) Standalone BLA
Overview
Source: Purple BookProprietary name
Rybrevant
Proper name
amivantamab-vmjw
Licence type
351(a)
BLA number
761210
Applicant
Janssen Biotech, Inc.
Center
CDER
Presentations
1
First licensure
—
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 350MG/7ML (50MG/ML) | Injection | Intravenous | Single-Dose Vial | Rx | May 21, 2021 |
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |